Literature DB >> 8076149

Increased expression of transforming growth factor-beta in renal disease.

M Ketteler1, N A Noble, W A Border.   

Abstract

Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine and a major regulator of tissue repair and extracellular matrix. Recent studies show that TGF-beta overexpression in experimental and human kidney diseases leads to progressive glomerular and tubulointerstitial scarring and renal failure. New evidence suggests that angiotensin-converting enzyme inhibitors and a low-protein diet may slow the progression of chronic kidney diseases in part by suppressing TGF-beta overexpression. New therapies may prevent progressive fibrosis in chronic kidney disease by suppressing the action of TGF-beta.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8076149     DOI： 10.1097/00041552-199407000-00011

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN： 1062-4821            Impact factor:   2.894


  8 in total

1.  Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.

Authors:  Sydney R Murphy; Annette J Dahly-Vernon; Kathryn M J Dunn; Chun Cheng Andy Chen; Steven R Ledbetter; Jan M Williams; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-04-25       Impact factor: 3.619

Review 2.  Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence.

Authors:  P August; B Leventhal; M Suthanthiran
Journal:  Curr Hypertens Rep       Date:  2000-04       Impact factor: 5.369

Review 3.  [Nitric oxide, L-arginine and the kidney. Experimental studies of new therapy approaches].

Authors:  M Ketteler; F Abou-Rebyeh; A Frey; A Gawlik; H Peters; R Westenfeld; A Distler
Journal:  Med Klin (Munich)       Date:  1998-01-15

Review 4.  A New Hypothetical Concept in Metabolic Understanding of Cardiac Fibrosis: Glycolysis Combined with TGF-β and KLF5 Signaling.

Authors:  Thanachai Methatham; Ryozo Nagai; Kenichi Aizawa
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

5.  TGFBI (βIG-H3) is a diabetes-risk gene based on mouse and human genetic studies.

Authors:  Bing Han; Hongyu Luo; John Raelson; Jie Huang; Yun Li; Johanne Tremblay; Bing Hu; Shijie Qi; Jiangping Wu
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

6.  Resistance to glomerulosclerosis in B6 mice disappears after menopause.

Authors:  Feng Zheng; Anna Rita Plati; Mylene Potier; Yvonne Schulman; Mariana Berho; Anita Banerjee; Baudouin Leclercq; Ariel Zisman; Liliane J Striker; Gary E Striker
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

7.  Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage.

Authors:  M Suthanthiran; B Li; J O Song; R Ding; V K Sharma; J E Schwartz; P August
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 8.  Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis.

Authors:  Kelly L Walton; Katharine E Johnson; Craig A Harrison
Journal:  Front Pharmacol       Date:  2017-07-14       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.